## **David Stepensky**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1056267/publications.pdf

Version: 2024-02-01

236833 243529 2,114 59 25 citations h-index g-index papers

60 60 60 3298 docs citations times ranked citing authors all docs

44

#	Article	IF	CITATIONS
1	Quantitative analysis of drug delivery to the brain via nasal route. Journal of Controlled Release, 2014, 189, 133-140.	4.8	245
2	Preclinical evaluation of pharmacokinetic–pharmacodynamic rationale for oral CR metformin formulation. Journal of Controlled Release, 2001, 71, 107-115.	4.8	115
3	Imaging Cancer Cells Expressing the Folate Receptor with Carbon Dots Produced from Folic Acid. ChemBioChem, 2016, 17, 614-619.	1.3	114
4	Pharmacokinetic-Pharmacodynamic Analysis of the Glucose-Lowering Effect of Metformin in Diabetic Rats Reveals First-Pass Pharmacodynamic Effect. Drug Metabolism and Disposition, 2002, 30, 861-868.	1.7	112
5	A Peptide Prodrug Approach for Improving Bisphosphonate Oral Absorption. Journal of Medicinal Chemistry, 2000, 43, 3641-3652.	2.9	104
6	Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. International Journal of Pharmaceutics, 2004, 277, 141-153.	2.6	103
7	Delivery of Gentamicin to the Rabbit Eye by Drug-Loaded Hydrogel Iontophoresis., 2004, 45, 2543.		102
8	Intracellular Targeting of PLGA Nanoparticles Encapsulating Antigenic Peptide to the Endoplasmic Reticulum of Dendritic Cells and Its Effect on Antigen Cross-Presentation <i>in Vitro</i> . Molecular Pharmaceutics, 2011, 8, 1266-1275.	2.3	93
9	Solubility and bioavailability of stabilized amorphous calcium carbonate. Journal of Bone and Mineral Research, 2011, 26, 364-372.	3.1	66
10	Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharmaceutical Research, 2002, 19, 1516-1523.	1.7	61
11	Bone as an Effect Compartment. Clinical Pharmacokinetics, 2003, 42, 863-881.	1.6	50
12	Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers. Journal of Clinical Pharmacology, 2003, 43, 711-720.	1.0	49
13	Limited Efficiency of Drug Delivery to Specific Intracellular Organelles Using Subcellularly "Targeted―Drug Delivery Systems. Molecular Pharmaceutics, 2016, 13, 1-7.	2.3	46
14	Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 1999, 16, 70.	1.2	44
15	Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. Journal of Controlled Release, 2012, 160, 315-321.	4.8	43
16	Delivery of drugs to intracellular organelles using drug delivery systems: Analysis of research trends and targeting efficiencies. International Journal of Pharmaceutics, 2015, 496, 268-274.	2.6	39
17	O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clinical and Experimental Immunology, 2006, 143, 139-149.	1.1	38
18	Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. Journal of Controlled Release, 2013, 171, 17-23.	4.8	38

#	Article	IF	CITATIONS
19	Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 381-389.	2.0	36
20	Efficient Subcellular Targeting to the Cell Nucleus of Quantum Dots Densely Decorated with a Nuclear Localization Sequence Peptide. ACS Applied Materials & Samp; Interfaces, 2016, 8, 2001-2009.	4.0	35
21	Pharmacokinetics of Glutamate–Oxaloacetate Transaminase and Glutamate–Pyruvate Transaminase and Their Blood Glutamate-Lowering Activity in NaÃ⁻ve Rats. Neurochemical Research, 2012, 37, 2198-2205.	1.6	33
22	Effect of Tomato Nutrient Complex on Blood Pressure: A Double Blind, Randomized Dose–Response Study. Nutrients, 2019, 11, 950.	1.7	32
23	FRETcalc plugin for calculation of FRET in non-continuous intracellular compartments. Biochemical and Biophysical Research Communications, 2007, 359, 752-758.	1.0	31
24	Longâ€term stability study of Lâ€adrenaline injections: Kinetics of sulfonation and racemization pathways of drug degradation. Journal of Pharmaceutical Sciences, 2004, 93, 969-980.	1.6	27
25	Bolaamphiphilic vesicles encapsulating iron oxide nanoparticles: New vehicles for magnetically targeted drug delivery. International Journal of Pharmaceutics, 2013, 450, 241-249.	2.6	26
26	Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. International Journal of Pharmaceutics, 2001, 220, 1-11.	2.6	25
27	Prediction of Drug Disposition on the Basis of its Chemical Structure. Clinical Pharmacokinetics, 2013, 52, 415-431.	1.6	25
28	Beta-casein nanocarriers of celecoxib for improved oral bioavailability. European Journal of Nanomedicine, 2014, 6, .	0.6	25
29	Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer. Journal of Controlled Release, 2018, 279, 1-7.	4.8	24
30	Aggregate Formation by ERp57â€Deficient MHC Class I Peptideâ€Loading Complexes. Traffic, 2007, 8, 1530-1542.	1.3	21
31	Combined Effects of Carotenoids and Polyphenols in Balancing the Response of Skin Cells to UV Irradiation. Molecules, 2021, 26, 1931.	1.7	21
32	Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharmaceutical Research, 1999, 16, 1399-1406.	1.7	19
33	A Signal Transduction Pharmacodynamic Model of the Kinetics of the Parasympathomimetic Activity of Low-Dose Scopolamine and Atropine in Rats. Journal of Pharmaceutical Sciences, 2002, 91, 2500-2510.	1.6	19
34	Pharmacokinetics of Toxin-Derived Peptide Drugs. Toxins, 2018, 10, 483.	1.5	19
35	Quantitative Aspects of Intracellularly-Targeted Drug Delivery. Pharmaceutical Research, 2010, 27, 2776-2780.	1.7	17
36	Nuclear and perinuclear targeting efficiency of quantum dots depends on density of peptidic targeting residues on their surface. Journal of Controlled Release, 2017, 257, 32-39.	4.8	17

#	Article	IF	CITATIONS
37	Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. Scientific Reports, 2021, 11, 7676.	1.6	17
38	Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis. Clinical Pharmacokinetics, 2012, 51, 443-455.	1.6	16
39	Use of unbound volumes of drug distribution in pharmacokinetic calculations. European Journal of Pharmaceutical Sciences, 2011, 42, 91-98.	1.9	15
40	Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic–pharmacodynamic modeling analysis. Journal of Clinical Pharmacology, 2014, 54, 1023-1030.	1.0	15
41	Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. Journal of Pharmaceutical Sciences, 2002, 91, 508-516.	1.6	14
42	â€~IntraCell' plugin for assessment of intracellular localization of nano-delivery systems and their targeting to the individual organelles. Biochemical and Biophysical Research Communications, 2011, 405, 228-233.	1.0	14
43	Therapeutic levetiracetam monitoring during pregnancy: "mind the gap― Therapeutic Advances in Chronic Disease, 2019, 10, 204062231985165.	1.1	14
44	Efficient Decoration of Nanoparticles Intended for Intracellular Drug Targeting with Targeting Residues, As Revealed by a New Indirect Analytical Approach. Molecular Pharmaceutics, 2014, 11, 2906-2914.	2.3	12
45	Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency. International Journal of Pharmaceutics, 2021, 592, 120012.	2.6	12
46	Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 41-52.	1.5	11
47	Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 767-784.	1.5	9
48	Celecoxib interferes to a limited extent with aspirinâ€mediated inhibition of platelets aggregation. British Journal of Clinical Pharmacology, 2016, 81, 316-326.	1.1	8
49	Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine. Pharmaceutical Research, 2001, 18, 1220-1225.	1.7	7
50	Mechanisms of cell death induced by infusion sets leachables in in vitro experimental settings. International Journal of Pharmaceutics, 2015, 478, 693-701.	2.6	7
51	Levetiracetam in lactation: How much is excreted into human breast milk?. British Journal of Clinical Pharmacology, 2022, 88, 199-205.	1.1	7
52	Toxicity assessment of extracts from infusion sets in cEND brain endothelial cells. International Journal of Pharmaceutics, 2012, 434, 20-27.	2.6	6
53	In vitro toxicity of infusion sets depends on their composition, storage time and storage conditions. International Journal of Pharmaceutics, 2015, 489, 285-293.	2.6	4
54	The Ã~ie–Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1233-1243.	1.5	3

#	Article	IF	CITATIONS
55	Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. Bioconjugate Chemistry, 2022, 33, 795-806.	1.8	3
56	Pharmacokinetics and Pharmacodynamics of Nano-Drug Delivery Systems. Fundamental Biomedical Technologies, 2016, , 341-362.	0.2	2
57	Magnitude of Lamotrigine Exposure Through Breastfeeding. Breastfeeding Medicine, 2022, 17, 341-348.	0.8	2
58	Delivery of Peptides and Proteins to the Brain Using Nano-Drug Delivery Systems and Other Formulations. Advances in Delivery Science and Technology, 2016, , 201-220.	0.4	1
59	Pharmacokinetic and Pharmacodynamic Aspects of Focal and Targeted Delivery of Drugs. Advances in Delivery Science and Technology, 2014, , 149-166.	0.4	1